

## CAR-T-Zelltherapie bei diffusem großzelligen B-Zell-Lymphom: eine bahnbrechende Behandlungsoption

1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. *CA Cancer J Clin* 2016;66:443–59.
2. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. *Oncogene* 2004;23:6524–34. (<https://www.nature.com/articles/1207843>).
3. van Leeuwen MT, Turner JJ, Joske DJ, et al. Lymphoid neoplasm incidence by WHO subtype in Australia 1982–2006. *Int J Cancer* 2014;135:2146–56.
4. Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. *Br J Cancer* 2011;105:1684–92.
5. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. *Blood* 2006;107:265–76.
6. Pfreundschuh M, Kuhnt E, Trümper L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MINT) Group. *Lancet Oncol* 2011;12:1013–22.
7. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *New England Journal of Medicine* 2002;346:235–42.
8. Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. *New England Journal of Medicine* 2022;386:351–63.
9. Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. *Blood* 2017;130:1800–8. (<https://pubmed.ncbi.nlm.nih.gov/28774879/>).
10. Boardman AP, Salles G. CAR T-cell therapy in large B cell lymphoma. *Hematol Oncol* 2023;41 Suppl 1:112–8. (<https://onlinelibrary.wiley.com/doi/10.1002/hon.3153>).
11. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucl CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *New England Journal of Medicine* 2017;377:2531–44.
12. Neelapu SS, Jacobson CA, Ghobadi A, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucl in refractory large B-cell lymphoma. *Blood* 2023;141:2307–15.
13. Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucl in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncol* 2019;20:31–42.
14. Riedell PA, Hwang W-T, Nastoupil LJ, et al. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucl and Tisagenlecleucl for Relapsed/Refractory Aggressive B Cell Lymphomas. *Transplantation and Cellular Therapy* 2022;28:669–76.
15. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. *New England Journal of Medicine* 2017;377:2545–54.
16. Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucl in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *New England Journal of Medicine* 2019;380:45–56.
17. Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucl in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol* 2021;22:1403–15.
18. Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucl for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. *Lancet* 2020;396:839–52.
19. Abramson JS, Palomba ML, Gordon LI, et al. Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucl (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL). *Blood* 2021;138:2840.
20. Kwon M, Iacoboni G, Reguera JL, et al. Axicabtagene ciloleucl compared to tisagenlecleucl for the treatment of aggressive B-cell lymphoma. *Haematologica* 2023;108:110–21.
21. Bachy E, Le Gouill S, Di Blasi R, et al. A real-world comparison of tisagenlecleucl and axicabtagene ciloleucl CAR T cells in relapsed or refractory diffuse large B cell lymphoma. *Nature Medicine* 2022;28:2145–54.
22. Riedell P. Lisocabtagene Maraleucl in Relapsed/Refractory Large B-Cell Lymphoma: Real World Analysis from the Cell Therapy Consortium. In: *ASH: ASH*.

23. Wudhikarn K, Pennisi M, Garcia-Recio M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. *Blood Advances* 2020;4:3024–33.
24. Abramson JS, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. *Blood* 2023;141:1675–84.
25. Bishop MR, Dickinson M, Purtil D, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. *New England Journal of Medicine* 2022;386:629–39.
26. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. *New England Journal of Medicine* 2022;386:640–54.
27. Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. *Lancet Oncol* 2022;23:1066–77.
28. Houot R, Bachy E, Cartron G, et al. Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. *Nature Medicine* 2023;29:2593–601. (<https://www.nature.com/articles/s41591-023-02572-5>).
29. Houot R, Bachy E, Cartron G, et al. S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY. *HemaSphere* 2023;7:e56791ba.
30. Diagnostik, Therapie und Nachsorge für erwachsene Patient\*innen mit einem diffusen großzelligen B-Zell-Lymphom und verwandten Entitäten, 2022, AWMF-Registernummer: 018/038OL. (<https://www.leitlinienprogramm.onkologie.de/leitlinien/dlbcl/>).
31. Georg Lenz, Björn Chapuy, Bertram Glaß, Felix Keil, Wolfram Klapper, Maike Nickelsen, Heinz Schmidberger, Clemens A. Schmitt, Urban Novak, Clemens-Martin Wendtner. *Onkopedia: Diffuses großzelliges B-Zell-Lymphom*, 2024. (<https://www.onkopedia.com/de/onkopedia/guidelines/diffuses-grosszelliges-b-zell-lymphom/@@guideline/html/index.html>).
32. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nature Medicine* 2018;24:679–90.
33. A predictive model for aggressive non-Hodgkin's lymphoma. *N Engl J Med* 1993;329:987–94.
34. Ruppert AS, Dixon JG, Salles G, et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. *Blood* 2020;135:2041–8.
35. Locke FL, Rossi JM, Neelapu SS, et al. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. *Blood Advances* 2020;4:4898–911.
36. Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. *Nature Medicine* 2022;28:735–42.
37. Chavez J. 3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL). In: ASH: ASH.
38. Westin J, Jacobson CA, Chavez JC, et al. ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma. *Journal of Clinical Oncology* 2023;41:TPS7578-TPS7578.
39. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *New England Journal of Medicine* 2013;368:1509–18.
40. Parker KR, Migliorini D, Perkey E, et al. Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. *Cell* 2020;183:126-142.e17.
41. Bennani NN, Maurer MJ, Nastoupil LJ, et al. Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. *Blood* 2019;134:763.
42. Frigault MJ, Dietrich J, Martinez-Lage M, et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. *Blood* 2019;134:860–6.
43. Frigault MJ, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. *Blood* 2022;139:2306–15.
44. Jacobson CA, Falvey C, Bouvier R, et al. A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL). *Blood* 2022;140:1060–1.
45. Ayuk F, Gagelmann N, Tresckow B v., et al. Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study. *Blood Advances* 2023;7:5316–9.
46. Cook MR, Dorris CS, Makambi KH, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. *Blood Advances* 2023;7:32–9.